Epitomee Medical Ltd

Tel Aviv Stock Exchange EPIT.TA

Epitomee Medical Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -125.04 K

Epitomee Medical Ltd Net Cash Used Provided By Financing Activities is USD -125.04 K for the year ending December 31, 2023, a -34.15% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Epitomee Medical Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -93.21 K, a -100.58% change year over year.
  • Epitomee Medical Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 16.13 M, a 664.12% change year over year.
  • Epitomee Medical Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 2.11 M, a -5.25% change year over year.
  • Epitomee Medical Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 2.23 M.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
Tel Aviv Stock Exchange: EPIT.TA

Epitomee Medical Ltd

CEO Dr. Radan Hashimshony Ph.D.
IPO Date Dec. 15, 2021
Location Israel
Headquarters 19 Tarshish
Employees 42
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. Its capsule is used for weight management, waist circumference reduction, and cardiovascular risk factors reduction. Epitomee Medical Ltd has a strategic partnership with Nestlé Health Science S.A. for the development and commercialization of the weight loss capsule. The company was incorporated in 2005 and is based in Caesarea, Israel.

StockViz Staff

January 30, 2025

Any question? Send us an email